S&P UPGRADES SANOFI TO STRONG BUY AFTER CLOSE THURSDAY
S&P raises opinion on shares of Sanofi to strong buy from hold. Quote..."We believe the shares, trading at 12.6X our 2015 EPS estimate of $3.57, below peers, are attractively valued. We keep our 12-mo. target at $57, on 16X our 2015 EPS estimate, in-line with peers, but below SNY's 5-year average of 18.3X. We think the shares have declined recently due to fears of increased diabetes drug competition, which we believe is overdone. SNY's diabetes portfolio grew 8.3% in Q3 in spite of a higher level of rebates on Lantus in the U.S. Notwithstanding continued heightened competition, we see the launches of Toujeo and Afrezza driving growth in 2015."
HEY !! Afrezza is DRIVING GROWTH!!
Take that YOU KRAP!!
I sincerely expect these kind of raids to happen more frequently as we get closer to launch!
PLEASE fellow longs, don't use stop losses. They are getting desperate and are stealing your shares when you put a STOP LOSS!!
there should be no doubt left. RBC has been doing a good job in following MNKD. I think they are the only ones with plain facts in their report. I like their upside scenario of $33 (Also reachable)
I warned everyone last week when we were at $4.68. I warn again this week.
We should see $6's later this week. SLOWLY they will build it up back to the $10 range before Jan.
IR THEMATIC SEMINAR ON NEW MEDICINES will happen on 11/20.
Sanofi will discuss both Afrezza and Toujeo. Both are registered trademarks of Sanofi
Mark your calendars.
so why don't they DEFEND the company!
Mannkind announces commercial manufacturing of Afrezza will start November 1,2014.
Mannkind expects first DELIVERY of manufactured product to Sanofi as part of their agreement on (date)
Initial order of Afrezza product by Sanofi is (x) dreamboat inhalers and (y) cartridges
Pricing for Afrezza has been determined at ($x) per cartridge
and on and on and on..
yeah ok. My opinion is that I believe the Pulitzer Prize Washington Post writer.
Also if you ever read the CNBC article that quotes Jason Krap about MNKD or the deceitful way AF seems to write about companies he makes wrong calls on, (MNKD again) and how he changes his tune every time he has to write about something. First it wasn't going to get approved, then comparing it to dance pharma (still at least 3 years away), then it can cause lung cancer, just look at the label, then they don't have a partner, then the partnership deal isn't good, and the latest one blame the drop on their bloated debt.
I can predict the next few choice AF articles - Well they have a nitche market, well their sales aren't going to live up to expectations, well endos and PCPs will not prescribe it and on and on.
AF reports with negativity and has a habit of pouncing on negative factors affecting a company. fr onece I'd like to see a FACTUAL AF article. Not going to see one ever.
9 am EST
Could it be:
1. Someone knew 10Q could be released today
2. Everyone knew Al was speaking today
3. They thus caused a Nasdaq circuit breaker yesterday in order to lock out the shorts from trading at all today?
Could they be that sophisticated?
We will find out by end of day I think.